These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9112505)

  • 21. [Long-term results of the treatment with intracavernous injection of vasoactive drugs].
    Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA
    Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction.
    McMahon CG; Samali R; Johnson H
    J Urol; 2000 Oct; 164(4):1192-6. PubMed ID: 10992364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1].
    Lemaire A; Buvat J
    Prog Urol; 1998 Jun; 8(3):388-91. PubMed ID: 9689672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice.
    Rajpurkar A; Dhabuwala CB
    J Urol; 2003 Jul; 170(1):159-63. PubMed ID: 12796670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reasons for high drop-out rate with self-injection therapy for impotence.
    Weiss JN; Badlani GH; Ravalli R; Brettschneider N
    Int J Impot Res; 1994 Sep; 6(3):171-4. PubMed ID: 7735362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction.
    Hirsch IH; Smith RL; Chancellor MB; Bagley DH; Carsello J; Staas WE
    Paraplegia; 1994 Oct; 32(10):661-4. PubMed ID: 7831071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
    Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
    Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
    Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
    Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic steps in the evaluation of patients with erectile dysfunction.
    Hatzichristou D; Hatzimouratidis K; Bekas M; Apostolidis A; Tzortzis V; Yannakoyorgos K
    J Urol; 2002 Aug; 168(2):615-20. PubMed ID: 12131320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
    Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
    Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compliance to longterm vasoactive intracavernous therapy.
    Pagliarulo A; Ludovico GM; Cirillo-Marucco E; Corvasce A; Pagliarulo G
    Int J Impot Res; 1996 Jun; 8(2):63-4. PubMed ID: 8858392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus.
    Israilov S; Shmuely J; Niv E; Engelstein D; Livne P; Boniel J
    Int J Impot Res; 2005; 17(5):431-6. PubMed ID: 15889124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostaglandin treatment in neurological patients with erectile dysfunction].
    Conejero Sugrañes J; Muñoz Villellas A; Sarrias Lorenz F; Ramírez Garceran L
    Arch Esp Urol; 2002; 55(1):63-8. PubMed ID: 11957754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Topical therapy in erectile dysfunction].
    Floth A
    Wien Med Wochenschr; 2000; 150(1-2):14-7. PubMed ID: 10746290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Methylene blue: an effective therapeutic alternative for priapism induced by intracavernous injection of vasoactive agents].
    Martínez Portillo FJ; Fernández Arancibia MI; Bach S; Alken P; Jünemann KP
    Arch Esp Urol; 2002 Apr; 55(3):303-8. PubMed ID: 12068762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experiences with intracavernous auto-injection for the treatment of erection disorders].
    van Deventer CP; Meuleman EJ; Bierkens PB; Sabbe BG; Smals AG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(8):408-12. PubMed ID: 8446199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis.
    Raina R; Lakin MM; Thukral M; Agarwal A; Ausmundson S; Montague DK; Klein E; Zippe CD
    Int J Impot Res; 2003 Oct; 15(5):318-22. PubMed ID: 14562131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracavernous injection as an option for aging men with erectile dysfunction.
    Wespes E
    Aging Male; 2002 Sep; 5(3):177-80. PubMed ID: 12471778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxicity of different intracavernous vasoactive drugs on cultured endothelial cells of human corpus cavernosum penis.
    Schultheiss D; Pilatz A; Gabouev AI; Schlote N; Wefer J; Mertsching H; Sohn M; Jonas U; Stief CG
    Urology; 2004 Sep; 64(3):598-602. PubMed ID: 15351616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.